Available online 25 November 2022

Post-transcriptional modifications in RNAs regulate their biological behaviors and functions. N1-methyladenosine (m1A), which is dynamically regulated by writers, erasers and readers, has been found as a reversible modification in tRNA, mRNA, rRNA and long non-coding RNA (lncRNA). m1A modification has impacts on the RNA processing, structure and functions of targets. Increasing studies reveal the critical roles of m1A modification and its regulators in tumorigenesis. Due to the positive relevance between m1A and cancer development, targeting m1A modification and m1A-related regulators has been of attention. In this review, we summarized the current understanding of m1A in RNAs, covering the modulation of m1A modification in cancer biology, as well as the possibility of targeting m1A modification as a potential target for cancer diagnosis and therapy.

5′ untranslated region

5-hydroxymethylcytosine

Abdominal aortic aneurysm

Acute myeloid leukemia

Bladder urothelial carcinoma

Fat mass and obesity-associated protein

Glioblastoma multiforme

Gastrointestinal cancer

Hepatocellular carcinoma

Long non-coding RNA

Mitochondrial tRNA

N6,2′-O-dimethyladenosine

Nonsteroidal anti-inflammatory drug

Non-small-cell lung cancer

Oral squamous cell carcinoma

R-2-hydroxyglutarate

S-adenosyl-L-methionine

tRNA methyltransferase 10C

tRNA methyltransferase 6

tRNA methyltransferase 61A

tRNA methyltransferase 61B

tRNA-derived small RNAs

Tumor microenvironment

YTH domain containing 1

YTH domain family protein 1

YTH domain family protein 2

YTH domain family protein 3

m1A

RNA

cancer biology

diagnosis

therapy

© 2022 The Author(s). Published by Elsevier B.V. on behalf of Research Network of Computational and Structural Biotechnology.